Maximal testosterone suppression in prostate cancer--free vs total testosterone

Urology. 2014 Jun;83(6):1217-22. doi: 10.1016/j.urology.2014.02.001. Epub 2014 Apr 6.

Abstract

Testosterone remains a key target in the treatment of advanced prostate cancer. The relationship of free testosterone to prostate cancer treatment and outcomes remains largely unexplored. A consensus of prostate cancer experts was convened in 2013 to review current knowledge surrounding relationship of total and free testosterone to prostate cancer, discuss the free hormone hypothesis, and highlight future avenues for therapeutics. Free testosterone may better reflect prostate cancer tissue androgen levels than serum total testosterone concentration. Free testosterone deserves more research regarding its relation to clinical outcomes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use*
  • Biomarkers, Tumor / blood
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Risk Assessment
  • Survival Analysis
  • Testosterone / analysis
  • Testosterone / antagonists & inhibitors*
  • Testosterone / metabolism*
  • Treatment Outcome

Substances

  • Androgen Antagonists
  • Biomarkers, Tumor
  • Testosterone
  • Prostate-Specific Antigen